Vaccine Production — Serum & Single-Use Bag Selection for Vero, MDCK & BHK-21
Viral vaccine manufacturing relies on continuous cell lines as the primary production platform — Vero for rabies, polio and dengue; MDCK for influenza; BHK-21 for foot-and-mouth disease, rabies and veterinary vaccines. Each cell line has specific serum requirements that directly impact virus propagation yield, cell health, and regulatory compliance. Post-COVID, global vaccine manufacturing capacity has expanded significantly and serum supply chain reliability has become a critical raw material risk. SeamlessBio supplies NCS, Calf Serum and FBS from EU, US and Australian origin with full BSE/TSE documentation for vaccine manufacturing applications.
Cell Line — Serum Selection Guide
| Cell Line | Vaccine Application | Recommended Serum | Concentration |
|---|---|---|---|
| Vero | Rabies (inactivated), Polio (IPV/OPV), Dengue, Japanese Encephalitis, Yellow Fever, SARS-CoV-2 | NCS ≤10 days — AU or US origin or FBS Low Endotoxin ≤5 EU/mL | 5–10% for maintenance; 2–5% during virus propagation |
| MDCK | Influenza (seasonal and pandemic), respiratory virus research | NCS ≤10 days — AU or US origin or FBS Low Endotoxin ≤5 EU/mL | 5–10% for cell maintenance; serum-free for virus infection step (trypsin-dependent influenza propagation) |
| BHK-21 | Foot-and-mouth disease (FMD), rabies, veterinary virus vaccines | CS — AU or US origin or FBS Low Endotoxin ≤5 EU/mL | 5–10% for routine culture; 2–5% during production phase |
| HEK293 | Adenoviral vectors for vaccine delivery, recombinant subunit vaccine production | FBS Low Endotoxin ≤5 EU/mL | 10% for maintenance; reduce to 2% or serum-free at production stage |
| CHO | Recombinant protein antigens, VLP (virus-like particle) production | FBS Low Endotoxin ≤5 EU/mL or serum-free | 5–10% for seed train; serum-free preferred at production scale |
| MRC-5 / WI-38 (diploid) | Varicella, hepatitis A, rabies (human diploid cell vaccine) | FBS Low Endotoxin ≤5 EU/mL | 10% — diploid cells require FBS quality; NCS/CS not recommended for primary diploid strains |
NCS vs Calf Serum vs FBS — Cost Optimisation for Vaccine Production
| Serum | Donor Age | Cost vs FBS | Best For | Not Suitable For |
|---|---|---|---|---|
| NCS ≤10 days | ≤10 days | ~30–50% lower | Vero, MDCK, BHK-21 routine maintenance and virus propagation. Rabies, influenza, FMD vaccine production. | Diploid cell strains (MRC-5, WI-38), sensitive primary cell cultures |
| Calf Serum (CS) | 14 days – 6 months | ~40–60% lower | BHK-21 large-scale FMD/veterinary vaccine production. High-volume cell banking programmes. | Diploid cells, applications requiring low IgG |
| FBS Low Endotoxin | Fetal | Reference | Diploid cell strains, HEK293 adenoviral vectors, CHO recombinant antigens, sensitive primary cell cultures | Cost-sensitive bulk Vero/MDCK/BHK-21 production where NCS/CS perform equivalently |
Origin Selection — BSE/TSE Documentation for Vaccine Submissions
| Origin | BSE/TSE Status | Documentation | Best For |
|---|---|---|---|
| Australian | OIE Negligible Risk — no indigenous BSE | EDQM CEP available, USDA import permitted | EU and US regulatory submissions requiring maximum TSE/BSE documentation. WHO-prequalified vaccine programmes. |
| US Origin | USDA 9CFR licensed | 9CFR CoA, FDA-aligned | US regulatory submissions. Cost-effective option for USDA-documented programmes. |
| EU Origin | EU TSE/BSE surveillance — controlled risk | EDQM CEP available | EU regulatory submissions. DACH market documentation requirements. |
Single-Use Bags for Vaccine Manufacturing
| Product | Volume | Vaccine Application | Key Specification |
|---|---|---|---|
| Rocker Bag | 0.5–200 L | Vero or MDCK cell expansion in rocking wave bioreactor for large-scale virus seed preparation. BHK-21 FMD vaccine scale-up. | USP Class VI. Gamma sterilised ≥25 kGy ISO 11137. Compatible with Corning and HyPerforma platforms. ISO 13485. |
| 2D Single-Use Bags | 150 mL–50 L | Virus harvest collection, media preparation, buffer storage, intermediate virus pools during downstream processing. | USP Class VI. Gamma sterilised. Drop-in for Sartorius Flexboy®. GMP documentation. ISO 13485 Germany. |
| 3D Single-Use Bags | 50–1,000 L | Large-volume media preparation for clinical-scale vaccine manufacturing. Buffer storage in cube containers. | MPX tubing. Full GMP documentation package. Gamma sterilised. ISO 13485. |
Vaccine Production Phases — Complete Product Map
| Phase | Step | Recommended Product |
|---|---|---|
| Cell Bank | MCB and WCB preparation for Vero, MDCK, BHK-21 | NCS AU origin — highest BSE documentation for cell bank regulatory filing |
| Seed Train | Cell expansion from WCB to production density | NCS or CS at 5–10% — cost-optimised expansion. Rocker Bags for suspension seed stages. |
| Infection | Virus inoculation and propagation | Reduce serum to 2–5% or switch to serum-free at infection step — reduces serum interference with virus quantification assays |
| Harvest | Virus harvest, clarification, primary purification | 2D Single-Use Bags for closed virus pool collection and storage |
| Formulation | Virus concentration, formulation, filling | BSA Low Endotoxin in stabilisation buffer if required |
Frequently Asked Questions
Can NCS replace FBS for Vero cell vaccine production?
Yes — for routine Vero cell maintenance and virus propagation (rabies, polio, dengue), NCS performs equivalently to FBS at 30–50% lower cost. NCS from calves ≤10 days provides a rich growth factor composition that supports Vero cell health and virus yield. Australian origin NCS provides the strongest regulatory documentation path for WHO-prequalified vaccine programmes.
Why is serum reduced or removed at the virus infection step?
High serum concentrations at the virus infection step can interfere with virus adsorption to cell surface receptors — reducing infection efficiency. Additionally, serum proteins interfere with plaque assay and TCID50 quantification of virus yield. Reducing serum to 2% or switching to serum-free medium during virus propagation is standard practice for Vero and MDCK-based vaccine production.
Which origin NCS for WHO-prequalified vaccine submissions?
Australian origin NCS is the preferred choice for WHO-prequalified vaccine programmes — OIE negligible BSE/TSE risk, EDQM CEP available, USDA import permitted. Australian origin provides the strongest regulatory documentation for both EU (EMA) and US (FDA) submissions and WHO prequalification dossiers.
What single-use bag for virus harvest collection?
2D Single-Use Bags in 2–10 L format are the standard for virus harvest collection from Vero or MDCK roller bottle or bioreactor runs. Closed system collection directly into gamma-sterilised bags minimises contamination risk and reduces handling steps. 3D bags in 50–200 L are used for pooled harvest intermediates in large-scale manufacturing.
Related Applications
| Application | Link |
|---|---|
| AAV & Viral Vector Production | AAV Viral Vector Guide → |
| Single-Use Bioprocessing | Single-Use Bags overview → |
| NCS product page | Newborn Calf Serum → |
Technical enquiries, batch reservation, origin documentation: info@seamlessbio.de | +49 851 37932226